Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03981445 · ClinicalTrials.gov registry record · NA
Integrated HIV Prevention and HCV Care for PWID
A NA study of Opioid Use and HIV Prevention, sponsored by Columbia University.
- Active
- Registry status
- NA
- Development phase
- 446
- Enrollment target
- 3
- Study locations
NCT03981445: Active NA study of Opioid Use and HIV Prevention, sponsored by Columbia University.
NCT03981445 is a NA study of Opioid Use and HIV Prevention that is active but no longer recruiting, run by Columbia University. The registered enrollment target is 446 participants, below the 148,256-participant average among 105 other Opioid Use trials with a reported enrollment target (100% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03981445, a NA study of Opioid Use and HIV Prevention, is active but no longer recruiting, sponsored by Columbia University.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 446 participants
- Enrollment target
- 3
- Study locations
Study Summary
The objective of this study is to compare and evaluate two strategies of delivering PrEP and Hepatitis C Virus (HCV) treatment to people who inject drugs to determine the best method of providing care. Participants will be randomized to one of two treatment arms: on-site integrated care or off-site referral to specialized care.
Primary Outcome
Average proportion of Dried Blood Spots (DBS) with detectable levels of Tenofovir at 6 months
Conditions Studied
Interventions
- BEHAVIORAL ARTAS Adapted Patient Navigation
- BEHAVIORAL Adherence Counseling
Study Locations (3)
Florida
- Miami - Miami
New York
- Columbia University Irving Medical Center - New York
Quebec
- Montreal - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 446 participants |
| Start Date | 2019-11-14 |
| Est. Completion | 2025-12-31 |
| Phase | NA |
What the registry record for NCT03981445 still lists
NCT03981445 is an interventional study that assigns participants to a tested intervention. The registered 446 participants enrollment target is mid-sized for trials with a published cap, below the 148,256-participant average among 105 other Opioid Use trials with a reported enrollment target (100% lower).
The record links to 4 conditions, with Opioid Use appearing as the primary indexed condition, and to 2 interventions - of which ARTAS Adapted Patient Navigation is the first listed.
NCT03981445 reports a single indexed study location in Florida, New York, Quebec.
Frequently Asked Questions
What is clinical trial NCT03981445 about?
NCT03981445 is a clinical study titled "Integrated HIV Prevention and HCV Care for PWID". The objective of this study is to compare and evaluate two strategies of delivering PrEP and Hepatitis C Virus (HCV) treatment to people who inject drugs to determine the best method of providing care. Participants will be randomized to one of two treatment arms: on-site integrated care or off-site ...
What is the current status of trial NCT03981445?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 446 participants. The study started on 2019-11-14. Estimated completion is 2025-12-31.
What conditions does trial NCT03981445 study?
This clinical trial studies the following conditions: Opioid Use, HIV Prevention, HCV, Intravenous Drug Usage.
What interventions are being tested in trial NCT03981445?
The interventions under investigation include: ARTAS Adapted Patient Navigation (BEHAVIORAL), Adherence Counseling (BEHAVIORAL).
Who is sponsoring clinical trial NCT03981445?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03981445 being conducted?
This trial has 3 study locations across Florida, New York, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Use
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03981445's enrollment target sits among peer trials
446 23rd of 105 higher than 83 of 105 other Opioid Use trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Opioid Use trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
QL vs LAI for Palatoplasty
RECRUITING · NA
-
Machine-Learning Prediction and Reducing Overdoses With EHR Nudges
RECRUITING · NA
-
Hip Arthroscopy Postoperative Opioid Demands
RECRUITING · NA
-
Neuroimaging of Opioid Phase (OPAL)
RECRUITING · NA
-
Encouraging Abstinence Behavior in a Drug Epidemic: Optimizing Dynamic Incentives
RECRUITING · NA
-
Opioid Prescribing Practices in Laparoscopic Gynecologic Surgery
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04065399 · 447 participants · Phase 1
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- NCT01280994 · 445 participants · Phase 2
Hyperpolarized 129Xe MRI for Imaging Pulmonary Function
- NCT03504800 · 445 participants
OCT in Diagnosis of Irregular Corneas
- NCT04751435 · 445 participants · NA
Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI